In a trial, the daily GLP-1 pill showed "significant" results and similar side effects to injectable GLP-1 drugs like Ozempic ...

A new oral anti-diabetes pill, orforglipron, shows similar effectiveness to injectable GLP-1 drugs in a Phase 3 trial.

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for diabetes and weight loss. Latest U.S.

New data from a Phase 3 trial show that the daily anti-obesity pill may be as safe and effective as drugs like Mounjaro and Ozempic for weight loss and lowering blood sugar.

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks ...

How effective is Eli Lilly’s new weight loss pill compared to ... Secretary Robert F. Kennedy Jr. Kennedy has been a critic of GLP-1 drugs, saying people should simply eat a healthier diet. ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, ... but also the processed food and diet industries that have fueled and capitalized on the obesity ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type 2 diabetes. Previous versions were administered via injection.

The blockbuster weight loss drug, semaglutide, now has competition in orforglipron, which is just as safe as injectable alternatives and more effectively lowers HbA1c (average blood sugar count of ...

Some new medications in development are also trying to solve for a persistent side effect of existing drugs: Patients who ...